The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis

  title={The Mechanism of Action of Interferon-$\beta$ in Relapsing Multiple Sclerosis},
  author={Bernd C. Kieseier},
  journal={CNS Drugs},
  • B. Kieseier
  • Published 1 June 2011
  • Biology, Medicine
  • CNS Drugs
Multiple sclerosis (MS) is characterized by autoimmune inflammation and subsequent neurodegeneration. It is believed that early in the disease course, proinflammatory T cells that are activated in the periphery by antigen presentation cross the blood-brain barrier (BBB) into the CNS directed by various chemotaxic agents. However, to date, there has been no formal demonstration of a specific precipitating antigen. Once inside the CNS, activated T cells including T helper-1 (Th1), Th17, γδ and… 
Interferon β-Mediated Protective Functions of Microglia in Central Nervous System Autoimmunity
The current understanding of the origin, phenotype, and function of microglia and CNS immigrating macrophages in the pathogenesis of MS and EAE is reviewed and the emerging roles ofmicroglia as IFNβ-producing cells and vice versa are highlighted.
Peripheral Biomarkers in Multiple Sclerosis Patients Treated with Interferon-Beta
The main goal of this chapter is to make an in-depth review of the major findings described in the literature that correlate specific alterations on different leukocytes subpopulations with disease status, and which therefore have the potential to constitute a peripheral biomarker of disease progression.
Interferon-β Suppresses Murine Th1 Cell Function in the Absence of Antigen-Presenting Cells
It is established that IFN-β inhibits mouse IFn-γ+ Th1 cell function in the absence of APCs and point to a novel mechanism of IFN -β-mediated T cell suppression that is independent of APC-derived signals.
The serum levels of the pro-inflammatory cytokines are higher in naïve recurrent-remissive multiple sclerosis patients compared to healthy controls, and treatment with Interferon-β significantly decreases the inflammatory profile.
Endogenous type I interferons and their regulators in multiple sclerosis
Further study delineating the role of endogenous type I IFN and their regulatory mechanisms in MS should enhance the understanding of the disease, and could lead to improvements in the therapeutic effects of IFN‐β in MS.
Direct immunomodulatory influence of IFN-β on human astrocytoma cells
A significant dose-dependent increase in IL-10 gene expression in A172 and 1321N1 cells treated with IFN-β or LPS/IFN-γ/IFn-β is found and a significant decrease was observed in iNOS expression suggesting a similar mechanism of action for both cells.
Elucidating the functions of fibroblast growth factor 9 in multiple sclerosis
It is indicated that increased levels of FGF9 are detrimental to myelination and neurons in the CNS and these studies provide evidence that FGF 9 can mediate these processes in in vitro and in vivo models.


Immunomodulatory effects of interferon beta-1a in multiple sclerosis
T cells in multiple sclerosis and experimental autoimmune encephalomyelitis
The contribution of Th1, Th17, γδ, CD8+ and regulatory T cells as well as the possible development of new therapeutic approaches for MS based on manipulating these T cell subtypes are reviewed.
Th17 Cells and autoimmune encephalomyelitis (EAE/MS).
  • T. Aranami, T. Yamamura
  • Biology, Medicine
    Allergology international : official journal of the Japanese Society of Allergology
  • 2008
It is demonstrated that human Th17 cells could be identified as CCR2+ CCR5- memory CD4+ T cells, and accumulating evidences raise a possibility that C CR2 on Th17 Cells may be a therapeutic target in MS.
Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis
This review describes recent and salient findings from animal models and human clinical studies that have established the current understanding of the distinct steps in the development of immune autoreactivity that culminates in the CNS lesions associated with MS.
An Interleukin (IL)-10/IL-12 Immunoregulatory Circuit Controls Susceptibility to Autoimmune Disease
It is demonstrated that interleukin (IL)-12 is essential for the generation of the autoreactive Th1 cells that induce EAE, both in the presence and absence of interferon γ.
Regulatory T cells in the control of inflammatory demyelinating diseases of the central nervous system
A better understanding of the induction of T regulatory cells, of their mechanisms of action, and of approaches to manipulate them in vivo may offer new therapeutic opportunities for patients with multiple sclerosis.
IL-1R Signaling within the Central Nervous System Regulates CXCL12 Expression at the Blood-Brain Barrier and Disease Severity during Experimental Autoimmune Encephalomyelitis1
It is suggested that T cell-derived IL-1β contributes to loss of immune privilege during CNS autoimmunity via pathologic alteration in the expression of CXCL12 at the BBB.
Interferon beta induces T-helper 2 immune deviation in MS
Interferon beta 1a (IFN-β) suppresses myelin basic protein (MBP)-reactive T cells and induces immune deviation toward the production of T-helper 2 cytokines, which may contribute to its therapeutic benefit in MS.
Interferon-β is neuroprotective against the toxicity induced by activated microglia
Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.
It is suggested that the clinical benefits of IFNbeta-1b treatment in MS patients may be in part a result of the ability of this drug to significantly decrease MMP-9 activity, leading to a reduction of T-lymphocyte infiltration into the CNS.